

## 7,8-dithydroxycoumarins protect human neuroblastoma cells from A $\beta$ -mediated neurotoxic damage via inhibiting JNK and p38MAPK pathways.

Guo-Min Liu<sup>1</sup>, Kun Xu<sup>2</sup>, Juan Li<sup>2</sup>, Yun-Gang Luo<sup>3\*</sup>

<sup>1</sup>Department of Orthopedics, the Second Hospital of Jilin University, Changchun, Jinlin, 130041, PR China

<sup>2</sup>Department of Health Laboratory, School of Public Health, Jilin University, Changchun 130021, PR China

<sup>3</sup>Department of Stomatology, the Second Hospital of Jilin University, Changchun, Jilin 130041, PR China

### Abstract

Neurons exposed to A $\beta$  will be apoptotic in Alzheimer's disease (AD) brains or *in vitro*. The aim of the current study is to explore the neuroprotective mechanism that 7,8-dithydroxycoumarin inhibits JNK and p38MAPK-mediated A $\beta$ -induced neurotoxicity.

*In vitro* cultures of SH-SY5Y human neuroblastoma cell lines were treated with 7,8-dithydroxycoumarin (0, 1, 5 and 10  $\mu$ mol/L) for 1.5 h, subsequently treated with 25  $\mu$ mol/L A $\beta$ 25-35 fibrils. The MTT method was used to detect cell proliferation, and fluorescence probe H2DCF-DA was used to determine intracellular reactive oxygen species (ROS) content. Western-blot assay was performed to detect the JNK and P38MAPK phosphorylation.

25  $\mu$ mol/L A $\beta$ 25-35 fibrils suppressed cell growth. They increased intracellular ROS, and enhanced levels of JNK and P38MAPK phosphorylation in a time-dependent manner. 7,8-dithydroxycoumarin treatment improved cell proliferation, reduced ROS generation and down-regulated levels of JNK and p38MAPK phosphorylation in a concentration-dependent manner.

7,8-dithydroxycoumarin may inhibit A $\beta$ -induced neurotoxic injury through suppressing ROS, JNK and p38MAPK pathways. The finding of the current study is conducive to protecting neurons in AD by using 7,8-dithydroxycoumarin.

**Keywords:**  $\beta$ -amyloid, Oxidative Stress, 7,8-dithydroxycoumarin, neuroprotection, JNK, p38MAPK.

Accepted on February 16, 2016

### Introduction

Alzheimer's disease (AD) is a neurodegenerative disorder with features of senile plaques, neurofibrillary tangles, and neuronal loss [1,2]. A $\beta$  accumulation plays a determining role in AD by inducing the apoptosis of neurons [3-6]. The intracellular mechanisms by which A $\beta$  triggers neuronal apoptosis involve oxidative stress [4,5], c-Jun N-terminal kinase (JNK) pathway and p38MAPK pathway [3-7]. How to prevent AD or attenuate disease progression is always a challenge [8-11].

7,8-dithydroxycoumarin (Daphnetin) is extracted from Daphne Korean Nakai and its chemical structure is shown in figure 1. It is a white or off-white, odourless, tasteless powder, and is sparingly soluble in methanol, slightly soluble in ethanol and insoluble in water. After absorption, 7,8-dithydroxycoumarin is widely distributed in body, and it is predominantly in kidney, also in lung, spleen and plasma [12,13]. Studies suggest that it can protect cardiovascular system, inhibit central nervous system and can pass through the blood brain barrier [12]. Upon its function in the brain, GAP-43 expression in ischemic hemisphere striatum and cortex is gradually increased after cerebral ischemia-reperfusion with 7,8-dithydroxycoumarin in

rats, and GAP-43 content in the whole ischemic hemisphere is increased to different extents [14]. Studies have suggested that 7,8-dithydroxycoumarin and coumarin derivatives can elevate expression of nerve growth factors (NGFs), promote proliferation of Schwann cells, protect neurons against damage, and accelerate regeneration of injured peripheral nerves [14-19]. In addition, coumarins are found to have antioxidant effects scavenging ROS [20]. Daphnetins can induce differentiation of human renal carcinoma cells by suppressing p38MAPK [21]. We asked might 7,8-dithydroxycoumarin protect neurons against A $\beta$ -induced neurotoxic injury by suppressing ROS and MAPK?

The current study is designed to investigate whether 7,8-dithydroxycoumarin inhibits A $\beta$ 25-35-induced neurotoxic injury through suppressing the JNK and p38MAPK pathways.

### Materials and Methods


#### Materials

7,8-dithydroxycoumarins (Daphnetins) were purchased from Enzo Life Sciences, Inc. (Shanghai, China). MTT was

purchased from Sigma-Aldrich (Shanghai, China). A $\beta$ 25-35 peptides were purchased from GL Biochem Ltd. (Shanghai, China). Prior to use, A $\beta$ 25-35 were dissolved in sterilized double-distilled water and its storage concentration was 2 mmol/L. Subsequently, they were incubated at 37°C for 7 days, turning to fibrillar form of A $\beta$ . Fluorescence probe 2',7'-dichlorodihydrofluorescein diacetate (H2DCF-DA) were purchased from Sangon Biotech (Shanghai, China). Mouse mAb antibodies of anti- $\beta$ -actin, anti-phospho-p38MAPK (Thr180/Tyr182), anti-p38MAPK, anti-JNK3 and anti-phospho-JNK (Thr183) were purchased from Sangon Biotech (Shanghai, China). Horse radish peroxidase-labeled secondary antibodies were purchased from Beyondtime Institute (Nanjing, Jiangsu, Chian). DAB chromogenic reagent kit and protein extract kit containing RIPA lysis solution were purchased from Boster Co.,Ltd., (Wuhan, Hubei, China).

### SH-SY5Y cell culture

SH-SY5Y human neuroblastoma cell lines were donated by Experimental Center of Jilin University Medical School. Cells were cultured in DMEM medium (containing penicillin of 100 IU/ml and streptomycin of 100 IU/ml) with 10% fetal bovine serum at 37°C under the condition of 5% CO<sub>2</sub>. In experiments, SH-SY5Y cells were inoculated into 96-well plates at a density of 1×10<sup>5</sup> per well (200  $\mu$ l medium per well) or 6-well plates at a density of 1×10<sup>6</sup> per well (2 ml per well) and incubated overnight. Then 7,8-dihydroxycoumarin (Daphnetins) shown in figure 1 at final concentrations of 0, 1, 5, 10  $\mu$ mol/l were added to cells and incubated for 1.5 h. Subsequently cells were treated with 25  $\mu$ mol/l A $\beta$ 25-35 fibrils.



**Figure 1.** Molecular structure of 7, 8-dihydroxycoumarins (Daphnetins).

### MTT assay

The MTT method was performed to assay the viability of SH-SY5Y cells. Briefly, 20  $\mu$ l (5 mg/ml) MTT was added in each well of 96-well plates, and the cells were incubated at 37°C for 4 h. After adding 150  $\mu$ l DMSO, the mixture was oscillated for 8 min. After purple crystals were fully dissolved, optical density (OD) values of each well was measured by the microplate reader. Cell viability was calculated by dividing normal control OD.

### Detection of intracellular ROS

H2DCF-DA is a new generation of ROS trapping agent. It can rapidly cross over cell membrane to enter cells and de-esterify under the effect of lactonase, generating nonluminous DCFH. When ROS such as H<sub>2</sub>O<sub>2</sub>, O<sup>2-</sup> and OH are present in cells, it is immediately oxidized into fluorescingenic 2',7'-dichlorodihydrofluorescein (DCF). At this time, it is feasible to determine the fluorescence intensity of intracellular DCF by flow cytometer or fluorescence microplate reader, namely conduct in situ real-time detection of intracellular ROS on the basis of single cell. Therefore, to change extent of intracellular free radicals can be directly detected by the fluorescence intensity. In this study, intracellular ROS was determined by the fluorescence probe H2DCF-DA staining method. H2DCF-DA was dissolved in DMSO. As staining, it was diluted with the medium to the working concentration. Cells in 96-well plates were incubated with fluorescence probe H2DCF-DA and incubated at 37°C for 15 min. Subsequently, the cells were washed with PBS for three times and detected using the fluorescence microplate reader. Fluorescent density percentage of cells was calculated by dividing normal control fluorescent density.

### Western-blot assay of protein expression

The RIPA cell lysis solution was added for cell lysis to extract proteins. After 10% SDS-PAGE electrophoresis, the proteins were electroblot to PDVF film and immersed in first antibodies (diluted by the ratio of 1:1000 in PBS containing 1% BSA) overnight at 4°C. The membranes were washed with 0.01 mol/l PBS for 4 times, 5 min each time, and then immersed in the second antibody goat anti-mouse IgG (1:10,000 diluted) at room temperature for 1 h. Afterwards, membranes were washed with 0.01 mol/l PBST, and color development was conducted according to the instructions of DAB chromogenic reagent kit. Band scanning and image analysis using ImageJ software [22] were carried out. Levels of phosphorylated JNK and p38MAPK were normalized on total JNK and p38MAPK, respectively.

### Statistical analysis


Data were expressed as mean  $\pm$  SEM. Statistical analysis was conducted by Graph Pad Prism 4.0 software (GraphPad software, Inc, San Diego, CA). Student t test was used for comparisons of two groups of data, and one-way ANOVA was used for multiple comparisons. P<0.05 indicated statistically significant differences.

## Results

### Cell viability

Fibrillar form of A $\beta$ 25-35 peptides can be used to mimic the effects of the A $\beta$ 1-40 fibrils, and 25  $\mu$ mol/l A $\beta$ 25-35 fibrils can effectively induce the apoptosis of primary cultured rat cortical neurons [3]. Hereby, 25  $\mu$ mol/l A $\beta$ 25-35 were selected in the current study to induce the injury of SH-SY5Y neuroblastoma

cells. Previous study has suggested that the concentrations of 7,8-dihydroxycoumarins (Daphnetins) ranging from 2 to 8  $\mu\text{mol/L}$  can promote neurite outgrowth and prolong neuronal survival time in primary cultured rat cortical neurons [15]. By referenced to this literature [15], the current study selected 1,5,10  $\mu\text{mol/L}$  Daphnetins for use. Effects of A $\beta$ 25-35 fibrils and 7,8-dihydroxycoumarins (Daphnetins) on SH-SY5Y cell viability were determined using the MTT assay. After treated with Daphnetins (0, 1, 5 and 10  $\mu\text{mol/L}$ ) for 1.5 h, the cells were treated with 25  $\mu\text{mol/l}$  A $\beta$ 25-35 fibrils. The results of MTT assay showed that A $\beta$ 25-35 remarkably reduced cell viability in a time-dependent manner (See Figure 2A). A $\beta$ 25-35-induced cell death was significantly inhibited by Daphnetins in a concentration-dependent manner, in particular 5 and 10  $\mu\text{mol/l}$  Daphnetins ( $P < 0.05$  (Figure 2B).




**Figure 2.** Effects of A $\beta$ 25-35 peptides and Daphnetins on SH-SY5Y cells. Cells were pre-treated with Daphnetins for 1.5 h, and then 25  $\mu\text{mol/l}$  A $\beta$ 25-35 was added. A: Time course of cell viability. 5  $\mu\text{mol/l}$  Daphnetins were used. B: Concentration-dependent effects at 24 h. \* $P < 0.05$  compared with the A $\beta$ 25-35 group,  $n = 5$ .

### Intracellular ROS

The mechanisms that A $\beta$  peptides induce neuronal injury and death involve oxidative stress. Fluorescence probe H2DCF-DA was used to detect the aggregation of intracellular ROS. After entering cells, H2DCF-DA was oxygenolysed by intracellular

peroxide and hydroperoxide into fluorescent dichlorofluorescein (DCF), and its fluorescence intensity was linear correlation to produced ROS concentration. For SH-SY5Y cells exposed to 25  $\mu\text{mol/l}$  A $\beta$ 25-35 fibrils, their fluorescence intensity was significantly increased in a time-dependent manner (See Figure 3A). Daphnetins pretreatment markedly reduced the A $\beta$ 25-35-induced intracellular ROS generation in a concentration-dependent manner (Figure 3B). Daphnetins could inhibit or clean A $\beta$ 25-35-induced ROS generation.




**Figure 3.** Influence of Daphnetins on ROS generation in SH-SY5Y cells exposed to A $\beta$ 25-35. Cells were pre-treated with Daphnetins for 1.5 h, and then 25  $\mu\text{mol/l}$  A $\beta$ 25-35 was added. A: Time course of ROS production. 5  $\mu\text{mol/l}$  Daphnetins were used. B: ROS production related to concentrations of Daphnetins at 24 h. \* $P < 0.05$  compared with the A $\beta$ 25-35 group,  $n = 5$ .

### Levels of JNK and p38MAPK phosphorylation induced by A $\beta$ 25-35 fibrils

Phosphorylation of JNK at threonine 183/tyrosine 185 (Thr183/Tyr185) site or phosphorylation of p38 MAPK at threonine 180/tyrosine 182 (Thr180/Tyr182) site are the main forms of their activation. The JNK pathway and p38MAPK pathway activations were assayed by Western blotting using phosphorylation site-specific antibodies, which recognized the phosphorylated forms of JNK and p38MAPK (Figures 4A and

4B). The Western blotting analysis showed that SH-SY5Y cells exposed to A $\beta$ 25-35 fibrils enhanced the phosphorylation of JNK and p38MAPK in a time-dependent manner (Figure 4A). Blots with antibodies that recognize JNK3 and p38MAPK regardless of their phosphorylation sites illustrated that the levels of total JNK3 and p38MAPK proteins were not affected by the treatment of A $\beta$ 25-35 to SH-SY5Y cells (Figures 4A and 4B). Daphnetins pretreatment attenuated the phosphorylation of JNK and p38MAPK in a dose-dependent manner (Figure 4B).



**Figure 4.** Western blots of p-JNK and p-p38MAPK. A $\beta$ 25-35 fibrils activate JNK and p38MAPK phosphorylation. Pretreatment with Daphnetins down-regulates their phosphorylation levels. Each blot was repeated three times. Levels of p-JNK and p-p38MAPK were normalized on total JNK and p38MAPK. (A) Concentrations of Daphnetins inhibit A $\beta$ 25-35-induced JNK and p38MAPK phosphorylation at 24 h. NC, normal control. (B) Time course of A $\beta$ 25-35-induced JNK and p38MAPK phosphorylation. Cells were pre-treated with 5  $\mu$ mol/l Daphnetins for 1.5 h, and then 25  $\mu$ mol/l A $\beta$ 25-35 were added.

## Discussion

Aggregation of A $\beta$  in the specific brain region mediates the oxidative stress (OS) damage to neurons. This plays an determining role in the pathogenesis and progression of AD [1-6,23]. A $\beta$  can induce OS *in vivo* and *in vitro*, and OS may increase the generation and aggregation of A $\beta$ . Such vicious cycles are formed between OS and A $\beta$ , promoting AD occurrence [1-6]. Considering the important role of OS in AD, the anti-OS treatment strategy is an effective treatment approach for occurrence and development of AD. Therefore, a broad-prospect method for prevention and treatment of AD may be weakening or inhibiting A $\beta$ -induced OS damage.

In the current study, fibrillar form of A $\beta$ 25-35 peptide was used to mimic the neurotoxic effects of A $\beta$ 1-40 fibrils, which can induce OS damage in neurons via multiple pathways. And 25  $\mu$ mol/l A $\beta$ 25-35 fibrils that have been reported to effectively induce the apoptosis of primary cultured rat cortical neurons within 24 h [3] were selected to induce the injury of SH-SY5Y neuroblastoma cells. 7,8-dihydroxycoumarin was expected to inhibit the A $\beta$ 25-35-induced neurotoxic injury via

suppressing oxidative damage or other signaling pathways as referenced to the literatures [20,21]. The concentrations of 1, 5, 10  $\mu$ mol/L Daphnetins were selected for use in the current study by referenced to the literature that have been reported 7,8-dihydroxycoumarins ranging from 2 to 8  $\mu$ mol/L can promote neurite outgrowth and prolong neuronal survival time in primary cultured rat cortical neurons [15].

The results demonstrated that 7,8-dihydroxycoumarin improved SH-SY5Y cell proliferation and inhibited A $\beta$ 25-35-induced intracellular ROS generation in a concentration-dependent manner (Figure 2).

OS is the main inductive substance activating the MAPK pathways [21]. The activation of JNK and p38MAPK is associated with neurotoxic damage, and A $\beta$  can activate these two kinases to induce neurotoxic injury [1-6,23]. The results in the current study demonstrated that A $\beta$ 25-35 enhanced JNK and p38MAPK phosphorylation with respect to elevated ROS production in SH-SY5Y neuroblastoma cells. 7,8-dihydroxycoumarin reduced the A $\beta$ 25-35-induced JNK and p38MAPK activation (Figure 4A and 4B) in a concentration-dependent manner. The MAPK pathways are essential to A $\beta$ -induced neurotoxic apoptosis [3]. Down-regulation of JNK and p38MAPK phosphorylation in the current study would attenuate the A $\beta$ -induced OS damage on neurons. These results suggested that 7,8-dihydroxycoumarin inhibited A $\beta$ 25-35-induced neurotoxic damage through suppressing JNK and p38MAPK activation.

Although 7,8-dihydroxycoumarin is promising to be applied to AD *in vitro*, homologous coumarins have a strong anti-coagulant effect. This pharmacological effect may pose some problems to its use *in vivo*. Therefore, animal experiments should be carefully performed for assessing the pharmacological effect of 7,8-dihydroxycoumarin *in vivo*. In addition, the neurotoxicity with respect to A $\beta$ 1-40 or A $\beta$ 1-42, neuron apoptosis, and their interaction with 7,8-dihydroxycoumarin should also be assessed in animal experiments in the future.

## Conclusion

In conclusion, 7,8-dihydroxycoumarin may inhibit the A $\beta$ 25-35-induced ROS generation and down-regulate JNK and p38MAPK pathways, playing its neuroprotective role. These results suggest that 7,8-dihydroxycoumarin might protect neurons in AD via inhibiting the JNK and p38MAPK activation. This study establishes a good foundation for investigating 7,8-dihydroxycoumarin as the drug for potential prevention and treatment of AD.

## References

1. Yankner BA. Mechanisms of neuronal degeneration in Alzheimer's disease. *Neuron*. 1996; 16: 921-932.
2. Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. *Nature*. 1999; 399: 23-31.
3. Morishima Y, Gotoh Y, Zieg J, Barrett T, Takano H, Flavell R, Davis RJ, Shirasaki Y, Greenberg ME. Beta-amyloid

*7,8-dihydroxycoumarins protect human neuroblastoma cells from A $\beta$ -mediated neurotoxic damage via inhibiting JNK and p38MAPK pathways*

- induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. *J Neurosci* 2001; 21: 7551-7560.
- Butterfield D, Drake J, Pocernich C, Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. *Trends Mol Med*. 2001; 7: 548-554
  - Kadowaki H, Nishitoh H, Urano F, Sadamitsu C, Matsuzawa A, Takeda K, Masutani H, Yodoi J, Urano Y, Nagano T, Ichijo H. Amyloid beta induces neuronal cell death through ROS-mediated ASK1 activation. *Cell Death Differ* 2005; 12: 19-24.
  - Tamagno E, Robino G, Obbili A, Bardini P, Aragno M, Parola M, Danni O. H<sub>2</sub>O<sub>2</sub> and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK. *Exp Neurol* 2003; 180: 144-155.
  - Wang X, Chen Q, Xing D. Focal adhesion kinase activates NF- $\kappa$ B via the ERK1/2 and p38MAPK Pathways in amyloid- $\beta$ 25-35-induced apoptosis in PC12 cells. *J Alzheimers Dis* 2012; 32: 77-94.
  - Wang S, Zhang C, Sheng X, Zhang X, Wang B, Zhang G. Peripheral expression of MAPK pathways in Alzheimer's and Parkinson's diseases. *J Clin Neurosci* 2014; 21: 810-814.
  - Yu DM, Fan WJ, Wu P, Deng JX, Liu J, Niu YL, Li MS, Deng JB. Characterization of hippocampal Cajal-Retzius cells during development in a mouse model of Alzheimer's disease (Tg2576). *Neural Regen Res* 2014; 9: 394-401.
  - Shen JN, Xu LX, Shan L, Zhang WD, Li HL, Wang R. Neuroprotection of (+)-2-(1-Hydroxyl-4-Oxocyclohexyl) Ethyl Caffeate Against Hydrogen Peroxide and Lipopolysaccharide Induced Injury via Modulating Arachidonic Acid Network and p38-MAPK Signaling. *Curr Alzheimer Res* 2015; 12: 892-902.
  - Roy SM, Grum-Tokars VL, Schavocky JP, Saeed F, Staniszewski A, Teich AF, Arancio O, Bachstetter AD, Webster SJ, Van Eldik LJ, Minasov G, Anderson WF, Pelletier JC, Watterson DM. Targeting human central nervous system protein kinases: An isoform selective p38 $\alpha$ MAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse models. *ACS Chem Neurosci* 2015; 6: 666-680.
  - Jurd L, Corse J, King AD Jr, Bayne H, Mihara K. Antimicrobial properties of 6,7-dihydroxy-, 7,8-dihydroxy-, 6-hydroxy- and 8-hydroxycoumarins. *Phytochemistry* 1971; 10: 2971-2974.
  - Juan Chen, Xia Liu, Yan Ping Shi. Determination of daphnetin in *Daphne tangutica* and its medicinal preparation by liquid chromatography. *Anal Chim Acta* 2004; 532: 29-33.
  - Sun M, Hu J, Song X, Wu D, Kong L, Sun Y, Wang D, Wang Y, Chen N, Liu G. Coumarin derivatives protect against ischemic brain injury in rats. *Eur J Med Chem* 2013; 67: 39-53.
  - Yan L, Zhou X, Zhou X, Zhang Z, Luo HM. Neurotrophic effects of 7,8-dihydroxycoumarin in primary cultured rat cortical neurons. *Neurosci Bull* 2012; 28: 493-498.
  - Du JS, Zhao Q, Zhang YL, Wang Y, Ma M. 7,8-dihydroxycoumarin may promote sciatic nerve regeneration by suppressing NF- $\kappa$ B expression in mice. *Mol Med Rep* 2013; 8: 1525-1530.
  - Yang L, Yang Q, Zhang K, Li YJ, Wu YM, Liu SB, Zheng LH, Zhao MG. Neuroprotective effects of daphnetin against NMDA receptor-mediated excitotoxicity. *Molecules* 2014; 19: 14542-14555.
  - Chen Z, Mao X, Liu A, Gao X, Chen X, Ye M, Ye J, Liu P, Xu S, Liu J, He W, Lian Q, Pi R. Osthole, a Natural Coumarin Improves Cognitive Impairments and BBB Dysfunction After Transient Global Brain Ischemia in C57 BL/6J Mice: Involvement of Nrf2 Pathway. *Neurochem Res* 2015; 40: 186-194.
  - Du G, Tu H, Li X, Pei A, Chen J, Miao Z, Li J, Wang C, Xie H, Xu X, Zhao H. Daphnetin, a natural coumarin derivative, provides the neuroprotection against glutamate-induced toxicity in HT22 cells and ischemic brain injury. *Neurochem Res*. 2014; 39: 269-275.
  - Filipský T, Říha M, Macáková K, Anzenbacherová E, Karličková J, Mladěnka P. Antioxidant effects of coumarins include direct radical scavenging, metal chelation and inhibition of ROS-producing enzymes. *Curr Top Med Chem* 2015; 15: 415-431.
  - Finn GJ, Creaven BS, Eqan DA. Daphnetin induced differentiation of human renal carcinoma cells and its mediation by p38 mitogen-activated protein kinase. *Biochem Pharmacol* 2004; 67: 1779-1788.
  - <http://imagej.nih.gov/ij/>
  - Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, Floyd RA, Butterfield DA. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. *Proc Natl Acad Sci USA* 1994; 91: 3270-3274.

**\*Correspondence to:**

Yun-Gang Luo

Department of Stomatology

The Second Hospital of Jilin University

PR China